Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) has announced that it has reached the halfway point in patient enrollment for its pilot multiple sclerosis (MS) imaging study conducted with Massachusetts General Hospital. Preliminary PET imaging data from the study have shown encouraging signals in acute MS lesions, according to a recent press release. This novel imaging technique is designed to differentiate between demyelinated nerve fibers that may still be viable and permanent nerve damage, potentially offering a more precise way to measure myelin loss and repair.
These findings are directly relevant to Lucid-MS, the company's investigational compound intended to inhibit demyelination by targeting the enzyme PAD2, which is implicated in myelin degradation. A more precise imaging tool and a drug candidate designed to address the underlying cause of MS make for a compelling combination. Reaching the enrollment midpoint with promising early data suggests the science is holding up under real clinical conditions.
Quantum BioPharma is a biopharmaceutical company focused on building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders, as well as alcohol misuse disorders, with drug candidates in various stages of development. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc. ("Lucid"), Quantum BioPharma is advancing the research and development of its lead compound, Lucid-MS. Lucid-MS is a patented new chemical entity that has been shown in preclinical models to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis.
In addition to its MS research, Quantum BioPharma has developed unbuzzd, a product intended to address alcohol misuse, and has spun out its over-the-counter version to a company, Unbuzzd Wellness Inc. ("UWI"), led by industry veterans. Quantum BioPharma retains a 19.84% ownership stake in UWI as of March 31, 2026, and is entitled to royalty payments of 7% of sales from unbuzzd until total payments reach $250 million, after which the royalty drops to 3% in perpetuity. The company retains 100% of the rights to develop similar products or alternative formulations specifically for pharmaceutical and medical uses.
The latest news and updates relating to Quantum BioPharma are available in the company's newsroom at https://ibn.fm/QNTM. For more information on the company's terms and disclaimers, visit http://IBN.fm/Disclaimer.
This announcement is significant because it provides early evidence that the imaging technique may offer a more accurate assessment of myelin damage, which could aid in monitoring disease progression and evaluating the efficacy of new therapies. For patients with MS, who currently face uncertainty about the extent of irreversible nerve damage, such a tool could improve clinical decision-making. For the industry, this advancement underscores the potential of precision imaging in neurodegenerative disease research and could accelerate the development of remyelinating therapies.
